ACCELERATE DIAGNOSTICS INC (AXDX) Stock Price, Quote, News and Overview
NASDAQ:AXDX - Nasdaq - US00430H2013 - Common Stock - Currency: USD
AXDX Quote, Performance and Key Statistics
1.19
+0.08 (+7.21%)
The current stock price of AXDX is 1.19 USD. In the past month the price increased by 3.48%. In the past year, price increased by 22.68%.
AXDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About AXDX
Company Profile
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The company is headquartered in Denver, Colorado and currently employs 134 full-time employees. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Company Info
ACCELERATE DIAGNOSTICS INC
3950 S Country Club Rd Ste 470 Bldg 3-307
Denver COLORADO 85714 US
CEO: Jack Phillips
Employees: 134
Company Website: http://acceleratediagnostics.com/
Investor Relations: https://ir.axdx.com/
Phone: 13038638088
ACCELERATE DIAGNOSTICS INC / AXDX FAQ
What is the stock price of ACCELERATE DIAGNOSTICS INC today?
The current stock price of AXDX is 1.19 USD. The price increased by 7.21% in the last trading session.
What is the ticker symbol for ACCELERATE DIAGNOSTICS INC stock?
The exchange symbol of ACCELERATE DIAGNOSTICS INC is AXDX and it is listed on the Nasdaq exchange.
On which exchange is AXDX stock listed?
AXDX stock is listed on the Nasdaq exchange.
What is ACCELERATE DIAGNOSTICS INC worth?
ACCELERATE DIAGNOSTICS INC (AXDX) has a market capitalization of 29.80M USD. This makes AXDX a Nano Cap stock.
How many employees does ACCELERATE DIAGNOSTICS INC have?
ACCELERATE DIAGNOSTICS INC (AXDX) currently has 134 employees.
What are the support and resistance levels for ACCELERATE DIAGNOSTICS INC (AXDX) stock?
ACCELERATE DIAGNOSTICS INC (AXDX) has a support level at 1.18 and a resistance level at 1.19. Check the full technical report for a detailed analysis of AXDX support and resistance levels.
Is ACCELERATE DIAGNOSTICS INC (AXDX) expected to grow?
The Revenue of ACCELERATE DIAGNOSTICS INC (AXDX) is expected to decline by -4.51% in the next year. Check the estimates tab for more information on the AXDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACCELERATE DIAGNOSTICS INC (AXDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AXDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AXDX, evaluating the profitability, health, valuation and growth aspects
- ACCELERATE DIAGNOSTICS INC (AXDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACCELERATE DIAGNOSTICS INC (AXDX) Sales and EPS estimates to see what analysts future expectations are.
- ACCELERATE DIAGNOSTICS INC (AXDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACCELERATE DIAGNOSTICS INC (AXDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACCELERATE DIAGNOSTICS INC (AXDX) Stock Chart to make your own analysis
- ACCELERATE DIAGNOSTICS INC (AXDX) Latest news and press-releases to stay up to date.
Does ACCELERATE DIAGNOSTICS INC (AXDX) stock pay dividends?
AXDX does not pay a dividend.
When does ACCELERATE DIAGNOSTICS INC (AXDX) report earnings?
ACCELERATE DIAGNOSTICS INC (AXDX) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of ACCELERATE DIAGNOSTICS INC (AXDX)?
ACCELERATE DIAGNOSTICS INC (AXDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).
What is the Short Interest ratio of ACCELERATE DIAGNOSTICS INC (AXDX) stock?
The outstanding short interest for ACCELERATE DIAGNOSTICS INC (AXDX) is 2.97% of its float. Check the ownership tab for more information on the AXDX short interest.
AXDX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AXDX. When comparing the yearly performance of all stocks, AXDX is a bad performer in the overall market: 65.72% of all stocks are doing better.
AXDX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AXDX. Both the profitability and financial health of AXDX have multiple concerns.
AXDX Financial Highlights
Over the last trailing twelve months AXDX reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS increased by 34.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -165.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AXDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to AXDX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 36.25% and a revenue growth -4.51% for AXDX